
Jan 12 (Reuters) - Amgen Inc AMGN.O:
AMGEN: 24-WEEK STUDY OF MONTHLY MARITIDE IN PEOPLE WITH TYPE 2 DIABETES SHOWED ROBUST, CLINICALLY MEANINGFUL REDUCTION IN BOTH HBA1C, WEIGHT
AMGEN: "LARGE MAJORITY" OF PEOPLE IN 52-WEEK MARITIDE EXTENSION STUDY GIVEN LOWER MONTHLY DOSE OR QUARTERLY DOSE OF DRUG MAINTAINED WEIGHT LOSS ACHIEVED IN PART 1 OF PHASE 2 TRIAL
AMGEN: SECOND YEAR OF MARITIDE TREATMENT VERY WELL TOLERATED INCLUDING AT QUARTERLY DOSES, WITH VERY LOW INCIDENCE OF NAUSEA, VOMITING & NO NEW SAFETY SIGNALS OBSERVED